Tue, Jul 22, 2014, 9:01 PM EDT - U.S. Markets closed


% | $
Click the to save as a favorite.

Synta Pharmaceuticals Corp. (SNTA) Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • amiretiredyet1 amiretiredyet1 Oct 1, 2012 9:37 PM Flag

    Hail, isn't this how the SYMMETRY mess went down?

    First, SYMMETRY went down precisely because there was no Phase 2b trial (which would have weeded out the high LDH patients).

    GALAXY not only has a Phase 2b trial, but a wildly successful Phase 2b trial. It's wildly successful because (a) the all-adeno results are excellent in their own right and (b) it's revealed enormous Hazard Ratio disparities ( 6 mo. = 0.37 ... Smokers = 1.61 vs. no-smoke = 0.48 ... No liver or bone metastatis = 0.41 vs. liver or bone metastatis well over 1.00 I'm sure).

    All 3 of these cuts of the data give p's = 0.023 or less for the low Hazard Ratio groups, i.e. they're statistically significant with room to spare. It only gets much better as these exclusions are combined and the number of patients tested (in Phase 3) goes up.

    The key point is that Synta will be able to use this valuable information (along with not-yet-reported biomarker research) to design its Phase 3 trial. It's hard to see how it can fail.

4.15+0.08(+1.97%)Jul 22 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Puma Biotechnology, Inc.
NYSETue, Jul 22, 2014 4:01 PM EDT
Microsoft Corporation
NasdaqGSTue, Jul 22, 2014 4:00 PM EDT